Investor Presentaiton

Research and Development Main Events / Targets for FY2023 (as of May 15, 2023) Psychiatry & Neurology Oncology Others Frontier ☐ ulotaront □ Obtain results from two Phase 3 studies for schizophrenia (□ DIAMOND 1 □ DIAMOND 2) (SEP-363856) ☐ Submit NDA for schizophrenia in the U.S. ☐ Advance Phase 2/3 study in Japan and China for schizophrenia □ Advance Phase 2/3 studies for two additional indications (aMDD, GAD) SEP-4199: Advance Phase 3 studies for Bipolar I depression Allogeneic iPS cell-derived products (Retinal pigment epithelium tear): Start clinical study in Japan ☐ Allogeneic iPS cell-derived products (Parkinson's disease): Start clinical study in the U.S. ☐ Complete manufacturing plant in the U.S. (for RETHYMICⓇ and allogeneic iPS cell-derived products) Advance early Phase studies ☐ relugolix: Obtain approval for endometriosis in Europe vibegron: Obtain results from Phase 3 study and submit sNDA for overactive bladder (OAB) with benign prostatic hyperplasia in the U.S. rodatristat ethyl: Obtain results from Phase 2 study for pulmonary arterial hypertension (PAH) ☐ universal influenza vaccine, malaria vaccines: Promote joint research and development projects Launch product: (Japan) Automated blood collection/stabilization device ☐ Promoting the current themes and generating evidence data for maximizing the value of the launched products Sumitomo Pharma © Sumitomo Pharma Co., Ltd. All Rights Reserved. 19

View entire presentation